Title: Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study
Abstract: CancerVolume 54, Issue 10 p. 2248-2256 ArticleFree Access Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study Barth Hoogstraten MD, Barth Hoogstraten MD Bethesda Hospital, Inc., Cincinnati, OhioSearch for more papers by this authorNazli Gad-El-Mawla MD, Nazli Gad-El-Mawla MD National Cancer Institute, Cairo, EgyptSearch for more papers by this authorThomas R. Maloney MD, Thomas R. Maloney MD University of Southern California School of Medicine, Los Angles, CaliforniaSearch for more papers by this authorWilliam S. Fletcher MD, William S. Fletcher MD University of Oregon Health Sciences Center, Eugene, OregonSearch for more papers by this authorClarence B. Vaughn MD, Clarence B. Vaughn MD Providence Hospital, Little Rock, ArkansasSearch for more papers by this authorBill L. Tranum MD, Bill L. Tranum MD University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorJohn W. Athens MD, John W. Athens MD University of Utah Medical Center, Salt Lake City, UtahSearch for more papers by this authorJohn J. Costanzi MD, John J. Costanzi MD University of Texas at Galveston, Galveston, TexasSearch for more papers by this authorMary Foulkes PHD, Mary Foulkes PHD Southwest Oncology Group Biostatistical Center, Houston, TexasSearch for more papers by this author Barth Hoogstraten MD, Barth Hoogstraten MD Bethesda Hospital, Inc., Cincinnati, OhioSearch for more papers by this authorNazli Gad-El-Mawla MD, Nazli Gad-El-Mawla MD National Cancer Institute, Cairo, EgyptSearch for more papers by this authorThomas R. Maloney MD, Thomas R. Maloney MD University of Southern California School of Medicine, Los Angles, CaliforniaSearch for more papers by this authorWilliam S. Fletcher MD, William S. Fletcher MD University of Oregon Health Sciences Center, Eugene, OregonSearch for more papers by this authorClarence B. Vaughn MD, Clarence B. Vaughn MD Providence Hospital, Little Rock, ArkansasSearch for more papers by this authorBill L. Tranum MD, Bill L. Tranum MD University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorJohn W. Athens MD, John W. Athens MD University of Utah Medical Center, Salt Lake City, UtahSearch for more papers by this authorJohn J. Costanzi MD, John J. Costanzi MD University of Texas at Galveston, Galveston, TexasSearch for more papers by this authorMary Foulkes PHD, Mary Foulkes PHD Southwest Oncology Group Biostatistical Center, Houston, TexasSearch for more papers by this author First published: 15 November 1984 https://doi.org/10.1002/1097-0142(19841115)54:10<2248::AID-CNCR2820541031>3.0.CO;2-DCitations: 31AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract The Southwest Oncology Group has completed a study of 213 women with the first recurrence of breast cancer. Eligibility included a radical or modified radical mastectomy for cure and recurrence which had received no other form of therapy. Patients were started on tamoxifen (TAM) 20 mg daily (Phase I). Failures, or responders who subsequently failed, had an oophorectomy if the ovaries were intact, and TAM was continued (Phase II). During Phase III, eligible patients underwent an adrenalectomy, and lastly, in Phase IV, patients received chemotherapy. Responses to TAM were seen in 40% of 56 premenopausal patients, 46% of 95 postmenopausal women, and 44% of 62 patients without intact ovaries. Oophorectomy plus TAM gave responses only in premenopausal women who failed to respond on TAM or in postmenopausal patients who had a prior response to TAM. Adrenalectomy was successful in 7 of 21 patients. Chemotherapy resulted in 13% complete and 47% partial responses. Median overall survival was 108, 155, and 115 weeks, respectively, for the three patient groups. The authors believe that until results with chemotherapy improve significantly, hormonal therapy is the preferred first-line management of recurrent breast cancer. Citing Literature Volume54, Issue1015 November 1984Pages 2248-2256 ReferencesRelatedInformation